Drug Profile

SAR 446523

Alternative Names: SAR-446523

Latest Information Update: 06 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sanofi-Aventis GmbH
Class Antibodies; Antineoplastics; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Multiple myeloma
New Molecular Entity Yes

Highest Development Phases

Phase I Multiple myeloma

Most Recent Events

30 Jul 2025 SAR 446523 receives Orphan Drug status for Multiple myeloma (Second-line therapy or greater) in USA
30 Oct 2024 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in Australia (SC) (NCT06630806)
08 Oct 2024 Sanofi plans a phase I trial for Multiple myeloma (Second-line therapy or greater) (SC) (NCT06630806)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com